Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Core Insights - Enliven Therapeutics has appointed Scott Garland to its Board of Directors as it transitions to late-stage development and commercialization of its drug ELVN-001, while Andrew Phillips, Ph.D., has resigned from the board [1][3] Leadership Changes - Scott Garland brings over 30 years of commercial leadership experience in the pharmaceutical industry, having held significant roles in companies such as PACT Pharma, Portola Pharmaceuticals, Relypsa, Exelixis, Genentech, Amgen, and Merck [2] - Rick Fair, CEO of Enliven, emphasized Garland's experience in oncology and hematology commercialization as crucial for advancing ELVN-001 into a pivotal Phase 3 trial [2] - Andrew Phillips expressed pride in the progress made during his tenure and acknowledged the need for board evolution as the company moves towards late-stage development [3] Clinical Development Focus - Following positive clinical data for ELVN-001 reported in 2025, Enliven is preparing to initiate a Phase 3 pivotal trial in 2026, aiming for potential commercialization [1][3] - The leadership changes, including the appointment of Rick Fair as CEO and Scott Garland to the board, reflect Enliven's commitment to aligning experienced governance with its transition into late-stage development [3] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving survival and overall well-being through precision oncology [5]